Alaethes Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

Alaethes Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.24M	Buy	4,502 +553	+14%	+$245K	0.65%	45
2026 Q1	$1.76M	Buy	3,949 +162	+4%	+$75.5K	0.5%	66
2025 Q4	$1.72M	Sell	3,787 -167	-4%	-$72K	0.48%	65
2025 Q3	$1.55M	Buy	3,954 +745	+23%	+$311K	0.44%	77
2025 Q2	$1.43M	Buy	3,209 +158	+5%	+$72.8K	0.43%	78
2025 Q1	$1.48M	Buy	+3,051	New	+$1.42M	0.54%	71
2022 Q2	–	Sell	-22	Closed	-$6K	–	284
2022 Q1	$6K	Hold	22	–	–	﹤0.01%	255
2021 Q4	$5K	Hold	22	–	–	﹤0.01%	238
2021 Q3	$4K	Hold	22	–	–	﹤0.01%	231
2021 Q2	$4K	Buy	+22	New	+$4.6K	﹤0.01%	224

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Alaethes Wealth's VRTX Position: Q2 2026 in Review

Alaethes Wealth increased its Vertex Pharmaceuticals (VRTX) stake by 14% in Q2 2026, buying an estimated $245K and bringing the position to 4,502 shares worth $2.24M. The position accounts for 0.65% of the portfolio, ranked #45.

Alaethes Wealth first reported a position in VRTX in Q2 2021 and has held it in 10 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Alaethes Wealth held 4,502 shares of Vertex Pharmaceuticals worth $2.24M as of Q2 2026.
Alaethes Wealth bought 553 Vertex Pharmaceuticals shares in Q2 2026, an estimated $245K.
Vertex Pharmaceuticals made up 0.65% of Alaethes Wealth's portfolio in Q2 2026, its #45 holding.
Alaethes Wealth first reported a position in Vertex Pharmaceuticals in Q2 2021 and has held it in 10 quarters since.
1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Alaethes Wealth's 13F filing for Q2 2026, filed 14 Aug 2026.